Current immunotherapeutic approaches in pancreatic cancer

Clinical and Developmental Immunology

Volumn 2011, Issue , 2011, Pages

  Koido, Shigeo ^a   Homma, Sadamu ^a   Takahara, Akitaka ^a   Namiki, Yoshihisa ^a   Tsukinaga, Shintaro ^a   Mitobe, Jimi ^a   Odahara, Shunichi ^a   Yukawa, Toyokazu ^a   Matsudaira, Hiroshi ^a   Nagatsuma, Keisuke ^a   Uchiyama, Kan ^a   Satoh, Kenichi ^a   Ito, Masaki ^a   Komita, Hideo ^a   Arakawa, Hiroshi ^a   Ohkusa, Toshifumi ^a   Gong, Jianlin ^b   Tajiri, Hisao ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CETUXIMAB; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; DNA TOPOISOMERASE INHIBITOR; DNA VACCINE; ERLOTINIB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOMODULATING AGENT; K RAS PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MARIMASTAT; MUCIN 1; PEPTIDE VACCINE; PLATINUM; RAS PROTEIN; SURVIVIN; TARACEVA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TIPIFARNIB; TRANSCRIPTION FACTOR FOXP3; TUMOR ANTIGEN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ADVANCED CANCER; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL GROWTH; CHEMORADIOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA REPLICATION; DNA STRAND BREAKAGE; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; METASTASIS; MULTIMODALITY CANCER THERAPY; PANCREAS CANCER; PANCREAS RESECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; TREATMENT OUTCOME; ANIMAL; CYTOTOXICITY; DRUG THERAPY; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; PANCREAS TUMOR; TUMOR ESCAPE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DRUG THERAPY; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; PANCREATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR ESCAPE;

EID: 81555221715     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2011/267539     Document Type: Review

References (131)

1. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010 CA Cancer Journal for Clinicians 2010 60 5 277 300
2. Sener S. F., Fremgen A., Menck H. R., Winchester D. P., Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 19851995, using the National Cancer Database Journal of the American College of Surgeons 1999 189 1 1 7 (Pubitemid 29307735)
3. Neoptolemos J. P., Stocken D. D., Friess H., Bassi C., Dunn J. A., Hickey H., Beger H., Fernandez-Cruz L., Dervenis C., Lacaine F., Falconi M., Pederzoli P., Pap A., Spooner D., Kerr D. J., A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer New England Journal of Medicine 2004 350 12 1200 1210 (Pubitemid 38339364)
4. Burris H. A. III, Moore M. J., Andersen J., Green M. R., Rothenberg M. L., Modiano M. R., Cripps M. C., Portenoy R. K., Storniolo A. M., Tarassoff P., Nelson R., Dorr F. A., Stephens C. D., Von Hoff D. D., Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial Journal of Clinical Oncology 1997 15 6 2403 2413 (Pubitemid 27251144)
5. Storniolo A. M., Allerheiligen S. R. B., Pearce H. L., Preclinical, pharmacologic, and phase I studies of gemcitabine Seminars in Oncology 1997 24 2, supplement 7 S7-2 S7-7
6. Berlin J. D., Catalano P., Thomas J. P., Kugler J. W., Haller D. G., Benson A. B. III, Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma Journal of Clinical Oncology 2002 20 15 3270 3275 (Pubitemid 34831525)
7. Lima C. M. R., Green M. R., Rotche R., Miller W. H., Jeffrey G. M., Cisar L. A., Morganti A., Orlando N., Gruia G., Miller L. L., Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate Journal of Clinical Oncology 2004 22 18 3776 3783 (Pubitemid 41095218)
8. Louvet C., Labianca R., Hammel P., Lledo G., Zampino M. G., André T., Zaniboni A., Ducreux M., Aitini E., Taeb J., Faroux R., Lepere C., De Gramont A., Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial Journal of Clinical Oncology 2005 23 15 3509 3516
9. Oettle H., Richards D., Ramanathan R. K., van Laethem J. L., Peeters M., Fuchs M., Zimmermann A., John W., Von Hoff D., Arning M., Kindler H. L., A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer Annals of Oncology 2005 16 10 1639 1645 (Pubitemid 41510138)
10. Abou-Alfa G. K., Letourneau R., Harker G., Modiano M., Hurwitz H., Tchekmedyian N. S., Feit K., Ackerman J., De Jager R. L., Eckhardt S. G., O'Reilly E. M., Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer Journal of Clinical Oncology 2006 24 27 4441 4447 (Pubitemid 46630982)
11. Bramhall S. R., Schulz J., Nemunaitis J., Brown P. D., Baillet M., Buckels J. A., A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer British Journal of Cancer 2002 87 2 161 167
12. Van Cutsem E., van de Velde H., Karasek P., Oettle H., Vervenne W. L., Szawlowski A., Schoffski P., Post S., Verslype C., Neumann H., Safran H., Humblet Y., Perez Ruixo J., Ma Y., Von Hoff D., Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer Journal of Clinical Oncology 2004 22 8 1430 1438 (Pubitemid 41103625)
13. Philip P. A., Benedetti J., Corless C. L., Wong R., O'Reilly E. M., Flynn P. J., Rowland K. M., Atkins J. N., Mirtsching B. C., Rivkin S. E., Khorana A. A., Goldman B., Fenoglio-Preiser C. M., Abbruzzese J. L., Blanke C. D., Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205 Journal of Clinical Oncology 2010 28 22 3605 3610
14. Van Cutsem E., Verslype C., Grusenmeyer P. A., Lessons learned in the management of advanced pancreatic cancer Journal of Clinical Oncology 2007 25 15 1949 1952 (Pubitemid 46972773)
15. Philip P. A., Improving treatment of pancreatic cancer The Lancet Oncology 2008 9 1 7 8
16. Cascinu S., Berardi R., Labianca R., Siena S., Falcone A., Aitini E., Barni S., Di Costanzo F., Dapretto E., Tonini G., Pierantoni C., Artale S., Rota S., Floriani I., Scartozzi M., Zaniboni A., Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial The Lancet Oncology 2008 9 1 39 44
17. Moore M. J., Goldstein D., Hamm J., Figer A., Hecht J. R., Gallinger S., Au H. J., Murawa P., Walde D., Wolff R. A., Campos D., Lim R., Ding K., Clark G., Voskoglou-Nomikos T., Ptasynski M., Parulekar W., Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group Journal of Clinical Oncology 2007 25 15 1960 1966 (Pubitemid 46972777)
18. Tobita K., Kijima H., Dowaki S., Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis International Journal of Molecular Medicine 2003 11 3 305 309
19. Ueda S., Ogata S., Tsuda H., Kawarabayashi N., Kimura M., Sugiura Y., Tamai S., Matsubara O., Hatsuse K., Mochizuki H., The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma Pancreas 2004 29 1 E1 E8
20. Ng S. S., Tsao M. S., Nicklee T., Hedley D. W., Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma Molecular Cancer Therapeutics 2002 1 10 777 783
21. Boon T., Coulie P. G., Van Den Eynde B., Tumor antigens recognized by T cells Immunology Today 1997 18 6 267 268 (Pubitemid 27261443)
22. Waldmann T. A., Immunotherapy: past, present and future Nature Medicine 2003 9 3 269 277 (Pubitemid 36362781)
23. Steinman R. M., Swanson J., The endocytic activity of dendritic cells Journal of Experimental Medicine 1995 182 2 283 288
24. Steinman R. M., The dendritic cell system and its role in immunogenicity Annual Review of Immunology 1991 9 271 296
25. Berard F., Blanco P., Davoust J., Neidhart-Berard E. M., Nouri-Shirazi M., Taquet N., Rimoldi D., Cerottini J. C., Banchereau J., Palucka A. K., Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells Journal of Experimental Medicine 2000 192 11 1535 1544
26. Finn O. J., Cancer immunology New England Journal of Medicine 2008 358 25 2704 2715
27. Dieli F., Gebbia N., Poccia F., Caccamo N., Montesano C., Fulfaro F., Arcara C., Valerio M. R., Meraviglia S., Di Sano C., Sireci G., Salerno A., Induction of T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo Blood 2003 102 6 2310 2311 (Pubitemid 37122416)
28. Zhu J., Paul W. E., Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors Immunological Reviews 2010 238 1 247 262
29. Banchereau J., Steinman R. M., Dendritic cells and the control of immunity Nature 1998 392 6673 245 252 (Pubitemid 28155090)
30. Bradley L. M., Yoshimoto K., Swain S. L., The cytokines IL-4, IFN-, and IL-12 regulate the development of subsets of memory effector helper T cells in vitro Journal of Immunology 1995 155 4 1713 1724
31. Wiethe C., Debus A., Mohrs M., Steinkasserer A., Lutz M., Gessner A., Dendritic cell differentiation state and their interaction with NKT cells determine Th1/Th2 differentiation in the murine model of Leishmania major infection Journal of Immunology 2008 180 7 4371 4381
32. Dong C., TH17 cells in development: an updated view of their molecular identity and genetic programming Nature Reviews Immunology 2008 8 5 337 348 (Pubitemid 351595217)
33. Canderan G., Dellabona P., T helper 17 T cells do good for cancer immunotherapy Immunotherapy 2010 2 1 21 24
34. Cannon M. J., Goyne H., Stone P. J.B., Chiriva-Internati M., Dendritic cell vaccination against ovarian cancer-tipping the Treg/T H17 balance to therapeutic advantage? Expert Opinion on Biological Therapy 2011 11 4 441 445
35. Koido S., Homma S., Hara E., Mitsunaga M., Namiki Y., Takahara A., Nagasaki E., Komita H., Sagawa Y., Ohkusa T., Fujise K., Gong J., Tajiri H., In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cells Journal of Translational Medicine 2008 6, article 51
36. Oji Y., Nakamori S., Fujikawa M., Nakatsuka S. I., Yokota A., Tatsumi N., Abeno S., Ikeba A., Takashima S., Tsujie M., Yamamoto H., Sakon M., Nezu R., Kawano K., Nishida S., Ikegame K., Kawakami M., Tsuboi A., Oka Y., Yoshikawa K., Aozasa K., Monden M., Sugiyama H., Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma Cancer Science 2004 95 7 583 587 (Pubitemid 39089639)
37. Ueda M., Miura Y., Kunihiro O., Ishikawa T., Ichikawa Y., Endo I., Sekido H., Togo S., Shimada H., MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT) Hepato-Gastroenterology 2005 52 62 398 403 (Pubitemid 40469434)
38. Seki K., Suda T., Aoyagi Y., Sugawara S., Natsui M., Motoyama H., Shirai Y., Sekine T., Kawai H., Mita Y., Waguri N., Kuroiwa T., Igarashi M., Asakura H., Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification Clinical Cancer Research 2001 7 7 1976 1981 (Pubitemid 32994834)
39. Gjertsen M. K., Bakka A., Breivik J., Saeterdal I., Solheim B. G., Soreide O., Thorsby E., Gaudernack G., Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation Lancet 1995 346 8987 1399 1400
40. Wobser M., Keikavoussi P., Kunzmann V., Weininger M., Andersen M. H., Becker J. C., Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin Cancer Immunology, Immunotherapy 2006 55 10 1294 1298 (Pubitemid 43992055)
41. Yamaguchi K., Enjoji M., Tsuneyoshi M., Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9 Journal of Surgical Oncology 1991 47 3 148 154
42. Komoto M., Nakata B., Amano R., Yamada N., Yashiro M., Ohira M., Wakasa K., Hirakawa K., HER2 overexpression correlates with survival after curative resection of pancreatic cancer Cancer Science 2009 100 7 1243 1247
43. Maacke H., Kessler A., Schmiegel W., Roeder C., Vogel I., Deppert W., Kalthoff H., Overexpression of p53 protein during pancreatitis British Journal of Cancer 1997 75 10 1501 1504 (Pubitemid 27196872)
44. Koido S., Homma S., Hara E., Namiki Y., Takahara A., Komita H., Nagasaki E., Ito M., Ohkusa T., Gong J., Tajiri H., Regulation of tumor immunity by tumor/dendritic cell fusions Clinical and Developmental Immunology 2010 2010
45. Mougiakakos D., Choudhury A., Lladser A., Kiessling R., Johansson C. C., Regulatory T cells in cancer Advances in cancer research 2010 107 57 117
46. Shevach E. M., Mechanisms of foxp3+ T regulatory cell-mediated suppression Immunity 2009 30 5 636 645
47. Purcell A. W., McCluskey J., Rossjohn J., More than one reason to rethink the use of peptides in vaccine design Nature Reviews Drug Discovery 2007 6 5 404 414 (Pubitemid 46696551)
48. Bijker M. S., Melief C. J., Offringa R., van der Burg S. H., Design and development of synthetic peptide vaccines: past, present and future Expert Review of Vaccines 2007 6 4 591 603 (Pubitemid 47281301)
49. Yanagimoto H., Mine T., Yamamoto K., Satoi S., Terakawa N., Takahashi K., Nakahara K., Honma S., Tanaka M., Mizoguchi J., Yamada A., Oka M., Kamiyama Y., Itoh K., Takai S., Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer Cancer Science 2007 98 4 605 611 (Pubitemid 46562753)
50. Miyazawa M., Ohsawa R., Tsunoda T., Hirono S., Kawai M., Tani M., Nakamura Y., Yamaue H., Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer Cancer Science 2010 101 2 433 439
51. Kanodia S., Kast W. M., Peptide-based vaccines for cancer: realizing their potential Expert Review of Vaccines 2008 7 10 1533 1545
52. Voskens C. J., Strome S. E., Sewell D. A., Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome Current Molecular Medicine 2009 9 6 683 693
53. Mocellin S., Pilati P., Nitti D., Peptide-based anticancer vaccines: recent advances and future perspectives Current Medicinal Chemistry 2009 16 36 4779 4796
54. Yanagimoto H., Takai S., Satoi S., Toyokawa H., Takahashi K., Terakawa N., Kwon A. H., Kamiyama Y., Impaired function of circulating dendritic cells in patients with pancreatic cancer Clinical Immunology 2005 114 1 52 60 (Pubitemid 39642790)
55. Koido S., Hara E., Homma S., Namiki Y., Komita H., Takahara A., Nagasaki E., Ito M., Sagawa Y., Mitsunaga M., Uchiyama K., Satoh K., Arihiro S., Ohkusa T., Gong J., Tajiri H., Dendritic/pancreatic carcinoma fusions for clinical use: comparative functional analysis of healthy- versus patient-derived fusions Clinical Immunology 2010 135 3 384 400
56. Gjertsen M. K., Buanes T., Rosseland A. R., Bakka A., Gladhaug I., Sreide O., Eriksen J. A., Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma International Journal of Cancer 2001 92 3 441 450 (Pubitemid 32249724)
57. Abou-Alfa G. K., Chapman P. B., Feilchenfeldt J., Brennan M. F., Capanu M., Gansukh B., Jacobs G., Levin A., Neville D., Kelsen D. P., O'Reilly E. M., Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine American Journal of Clinical Oncology 2011 34 3 321 325
58. Yamamoto K., Ueno T., Kawaoka T., Hazama S., Fukui M., Suehiro Y., Hamanaka Y., Ikematsu Y., Imai K., Oka M., Hinoda Y., MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer Anticancer Research 2005 25 5 3575 3579 (Pubitemid 41105243)
59. Ramanathan R. K., Lee K. M., McKolanis J., Hitbold E., Schraut W., Moser A. J., Warnick E., Whiteside T., Osborne J., Kim H., Day R., Troetschel M., Finn O. J., Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer Cancer Immunology, Immunotherapy 2005 54 3 254 264 (Pubitemid 40174243)
60. Bernhardt S. L., Gjertsen M. K., Trachsel S., Mller M., Eriksen J. A., Meo M., Buanes T., Gaudernack G., Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study British Journal of Cancer 2006 95 11 1474 1482 (Pubitemid 44863349)
61. Itoh K., Yamada A., Mine T., Noguchi M., Recent advances in cancer vaccines: an overview Japanese Journal of Clinical Oncology 2009 39 2 73 80
62. Yamamoto K., Mine T., Katagiri K., Suzuki N., Kawaoka T., Ueno T., Matsueda S., Yamada A., Itoh K., Yamana H., Oka M., Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancer Oncology Reports 2005 13 5 874 883
63. Melief C. J. M., van der Burg S. H., Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines Nature Reviews Cancer 2008 8 5 351 360 (Pubitemid 351589701)
64. Bijker M. S., van den Eeden S. J. F., Franken K. L., Melief C. J. M., van der Burg S. H., Offringa R., Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation European Journal of Immunology 2008 38 4 1033 1042
65. Wedén S., Klemp M., Gladhaug I. P., Mller M., Eriksen J. A., Gaudernack G., Buanes T., Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras International Journal of Cancer 2011 128 5 1120 1128
66. Koido S., Hara E., Homma S., Torii A., Toyama Y., Kawahara H., Watanabe M., Yanaga K., Fujise K., Tajiri H., Gong J., Toda G., Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells Clinical Cancer Research 2005 11 21 7891 7900 (Pubitemid 41611636)
67. Jaffee E. M., Hruban R. H., Biedrzycki B., Laheru D., Schepers K., Sauter P. R., Goemann M., Coleman J., Grochow L., Donehower R. C., Lillemoe K. D., O'Reilly S., Abrams R. A., Pardoll D. M., Cameron J. L., Yeo C. J., Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation Journal of Clinical Oncology 2001 19 1 145 156 (Pubitemid 32063491)
68. Laheru D., Biedrzycki B., Jaffee E. M., Immunologic approaches to the management of pancreatic cancer Cancer Journal 2001 7 4 324 337
69. Hege K. M., Jooss K., Pardoll D., GM-CSF gene-modifed cancer cell immunotherapies: of mice and men International Reviews of Immunology 2006 25 5-6 321 352 (Pubitemid 44972270)
70. Laheru D., Lutz E., Burke J., Biedrzycki B., Solt S., Onners B., Tartakovsky I., Nemunaitis J., Le D., Sugar E., Hege K., Jaffee E., Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation Clinical Cancer Research 2008 14 5 1455 1463 (Pubitemid 351413929)
71. Frster R., Schubel A., Breitfeld D., Kremmer E., Renner-Mller I., Wolf E., Lipp M., CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs Cell 1999 99 1 23 33 (Pubitemid 29468627)
72. Banchereau J., Palucka A. K., Dendritic cells as therapeutic vaccines against cancer Nature Reviews Immunology 2005 5 4 296 306 (Pubitemid 40516155)
73. Nestle F. O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D., Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nature Medicine 1998 4 3 328 332 (Pubitemid 28144092)
74. Mackensen A., Herbst B., Chen J. L., Khler G., Noppen C., Herr W., Spagnoli G. C., Cerundolo V., Lindemann A., Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells International Journal of Cancer 2000 89 2 385 392 (Pubitemid 30187500)
75. Palucka A. K., Ueno H., Connolly J., Kerneis-Norvell F., Blanck J. P., Johnston D. A., Fay J., Banchereau J., Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity Journal of Immunotherapy 2006 29 5 545 557 (Pubitemid 44395279)
76. Nair S. K., Boczkowski D., Morse M., Cumming R. I., Lyerly H. K., Gilboa E., Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA Nature Biotechnology 1998 16 4 364 369 (Pubitemid 28164657)
77. Leitner W. W., Ying H., Restifo N. P., DNA and RNA-based vaccines: principles, progress and prospects Vaccine 1999 18 9-10 765 777
78. Gilboa E., Vieweg J., Cancer immunotherapy with mRNA-transfected dendritic cells Immunological Reviews 2004 199 251 263 (Pubitemid 38744521)
79. Gong J., Chen D., Kashiwaba M., Kufe D., Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells Nature Medicine 1997 3 5 558 561 (Pubitemid 27198656)
80. Koido S., Hara E., Homma S., Fujise K., Gong J., Tajiri H., Dendritic/tumor fusion cell-based vaccination against cancer Archivum Immunologiae et Therapiae Experimentalis 2007 55 5 281 287
81. Gong J., Koido S., Calderwood S. K., Cell fusion: from hybridoma to dendritic cell-based vaccine Expert Review of Vaccines 2008 7 7 1055 1068
82. Koido S., Hara E., Homma S., Ohkusa T., Gong J., Tajiri H., Cancer immunotherapy by fusions of dendritic cells and tumor cells Immunotherapy 2009 1 1 49 62
83. Avigan D., Vasir B., Gong J., Borges V., Wu Z., Uhl L., Atkins M., Mier J., McDermott D., Smith T., Giallambardo N., Stone C., Schadt K., Dolgoff J., Tetreault J. C., Villarroel M., Kufe D., Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses Clinical Cancer Research 2004 10 14 4699 4708 (Pubitemid 38955520)
84. Kikuchi T., Akasaki Y., Abe T., Fukuda T., Saotome H., Ryan J. L., Kufe D. W., Ohno T., Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12 Journal of Immunotherapy 2004 27 6 452 459 (Pubitemid 39447353)
85. Homma S., Kikuchi T., Ishiji N., Ochiai K., Takeyama H., Saotome H., Sagawa Y., Hara E., Kufe D., Ryan J. L., Ohno T., Toda G., Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12 European Journal of Clinical Investigation 2005 35 4 279 286 (Pubitemid 40546927)
86. Homma S., Sagawa Y., Ito M., Ohno T., Toda G., Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses Clinical and Experimental Immunology 2006 144 1 41 47
87. Tang C. K., Katsara M., Apostolopoulos V., Strategies used for MUC1 immunotherapy: human clinical studies Expert Review of Vaccines 2008 7 7 963 975
88. Lepisto A. J., Moser A. J., Zeh H., A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors Cancer Therapy 2008 6 B 955 964
89. Pecher G., Hring A., Kaiser L., Thiel E., Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial Cancer Immunology, Immunotherapy 2002 51 11-12 669 673 (Pubitemid 35446294)
90. Beatty G. L., Vonderheide R. H., Telomerase as a universal tumor antigen for cancer vaccines Expert Review of Vaccines 2008 7 7 881 887
91. Sbe-Larssen S., Fossberg E., Gaudernack G., mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT) Journal of Immunological Methods 2002 259 1-2 191 203 (Pubitemid 33124396)
92. Brunsvig P. F., Aamdal S., Gjertsen M. K., Kvalheim G., Markowski-Grimsrud C. J., Sve I., Dyrhaug M., Trachsel S., Mller M., Eriksen J. A., Gaudernack G., Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer Cancer Immunology, Immunotherapy 2006 55 12 1553 1564 (Pubitemid 44327843)
93. Suso E. M.I., Dueland S., Rasmussen A. -M., Vetrhus T., Aamdal S., Kvalheim G., Gaudernack G., hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes Cancer Immunology, Immunotherapy 2011 1 10
94. Kimura Y., Imai K., Shimamura K., Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in the patients with advanced pancreatic carcinoma. Pancreas. In press
95. Eschenburg G., Stermann A., Preissner R., Meyer H. -A., Lode H. N., DNA vaccination: using the patient's immune system to overcome cancer Clinical and Developmental Immunology 2010 2010
96. Rong Y., Jin D., Wu W., Lou W., Wang D., Kuang T., Ni X., Qin X., Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine BMC Cancer 2009 9, article 191
97. Zhu K., Qin H., Cha S. C., Neelapu S. S., Overwijk W., Lizee G. A., Abbruzzese J. L., Hwu P., Radvanyi L., Kwak L. W., Chang D. Z., Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models Vaccine 2007 25 46 7955 7961 (Pubitemid 47632978)
98. Gabrilovich D. I., Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited Lancet Oncology 2007 8 1 2 3 (Pubitemid 44943085)
99. Smith B. D., Kasamon Y. L., Kowalski J., Gocke C., Murphy K., Miller C. B., Garrett-Mayer E., Tsai H. L., Qin L., Chia C., Biedrzycki B., Harding T. C., Tu G. H., Jones R., Hege K., Levitsky H. I., K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate Clinical Cancer Research 2010 16 1 338 347
100. Plate J. M., Plate A. E., Shott S., Bograd S., Harris J. E., Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas Cancer Immunology, Immunotherapy 2005 54 9 915 925 (Pubitemid 40991334)
101. Hou J. M., Liu J. Y., Yang L., Zhao X., Tian L., Ding Z. Y., Wen Y. J., Niu T., Xiao F., Lou Y. Y., Tan G. H., Deng H. X., Li J., Yang J. L., Mao Y. Q., Wei Y. Q., Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities Oncology 2005 69 1 81 87 (Pubitemid 41207061)
102. Soeda A., Morita-Hoshi Y., Makiyama H., Morizane C., Ueno H., Ikeda M., Okusaka T., Yamagata S., Takahashi N., Hyodo I., Takaue Y., Heike Y., Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer Japanese Journal of Clinical Oncology 2009 39 12 797 806
103. Correale P., Cusi M. G., Del Vecchio M. T., Aquino A., Prete S., Tsang K. Y., Micheli L., Nencini C., La Placa M., Montagnani F., Terrosi C., Caraglia M., Formica V., Giorgi G., Bonmassar E., Francini G., Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro Journal of Immunology 2005 175 2 820 828 (Pubitemid 41094964)
104. Nowak A. K., Lake R. A., Marzo A. L., Scott B., Heath W. R., Collins E. J., Frelinger J. A., Robinson B. W. S., Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells Journal of Immunology 2003 170 10 4905 4913 (Pubitemid 36554719)
105. Nowak A. K., Robinson B. W. S., Lake R. A., Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors Cancer Research 2003 63 15 4490 4496 (Pubitemid 36951021)
106. Dauer M., Herten J., Bauer C., Renner F., Schad K., Schnurr M., Endres S., Eigler A., Chemosensitization of pancreatic carcinoma cells to enhance T cell-mediated cytotoxicity induced by tumor lysate-pulsed dendritic cells Journal of Immunotherapy 2005 28 4 332 342 (Pubitemid 40962326)
107. Suzuki E., Kapoor V., Jassar A. S., Kaiser L. R., Albelda S. M., Gemcitabine selectively eliminates splenic Gr-1+/CD11b + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clinical Cancer Research 2005 11 18 6713 6721 (Pubitemid 41339014)
108. Nagaraj S., Youn J. I., Weber H., Iclozan C., Lu L., Cotter M. J., Meyer C., Becerra C. R., Fishman M., Antonia S., Sporn M. B., Liby K. T., Rawal B., Lee J. H., Gabrilovich D. I., Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer Clinical Cancer Research 2010 16 6 1812 1823
109. Bauer C., Bauernfeind F., Sterzik A., Orban M., Schnurr M., Lehr H. A., Endres S., Eigler A., Dauer M., Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model Gut 2007 56 9 1275 1282 (Pubitemid 47300430)
110. Ramakrishnan R., Assudani D., Nagaraj S., Hunter T., Cho H. I., Antonia S., Altiok S., Celis E., Gabrilovich D. I., Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice Journal of Clinical Investigation 2010 120 4 1111 1124
111. Weng D., Song B., Durfee J., Sugiyama V., Wu Z., Koido S., Calderwood S. K., Gong J., Induction of cytotoxic T lymphocytes against ovarian cancer-initiating cells International Journal of Cancer 2011 129 8 1990 2001
112. Wang Z., Li Y., Ahmad A., Banerjee S., Azmi A. S., Kong D., Sarkar F. H., Pancreatic cancer: understanding and overcoming chemoresistance Nature Reviews Gastroenterology and Hepatology 2011 8 1 27 33
113. Dean M., Fojo T., Bates S., Tumour stem cells and drug resistance Nature Reviews Cancer 2005 5 4 275 284 (Pubitemid 40488633)
114. Du Z., Qin R., Wei C., Wang M., Shi C., Tian R., Peng C., Pancreatic cancer cells resistant to chemoradiotherapy rich in stem-cell-like tumor cells Digestive Diseases and Sciences 2010 56 3 741 750
115. Li C., Heidt D. G., Dalerba P., Burant C. F., Zhang L., Adsay V., Wicha M., Clarke M. F., Simeone D. M., Identification of pancreatic cancer stem cells Cancer Research 2007 67 3 1030 1037
116. Lee C. J., Dosch J., Simeone D. M., Pancreatic cancer stem cells Journal of Clinical Oncology 2008 26 17 2806 2812
117. Wang Y. H., Li F., Luo B., Wang X. H., Sun H. C., Liu S., Cui Y. Q., Xu X. X., A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics Neoplasma 2009 56 5 371 378
118. Zhang S. -N., Huang F. -T., Huang Y. -J., Zhong W., Yu Z., Characterization of a cancer stem cell-like side population derived from human pancreatic adenocarcinoma cells Tumori 2010 96 6 985 992
119. Sung P. H., Wen J., Bang S., Park S., Si Y. S., CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells International Journal of Cancer 2009 125 10 2323 2331
120. Inoda S., Hirohashi Y., Torigoe T., Morita R., Takahashi A., Asanuma H., Nakatsugawa M., Nishizawa S., Tamura Y., Tsuruma T., Terui T., Kondo T., Ishitani K., Hasegawa T., Hirata K., Sato N., Cytotoxic T lymphocytes efficiently recognize human colon cancer stem-like cells American Journal of Pathology 2011 178 4 1805 1813
121. Hirohashi Y., Torigoe T., Inoda S., Takahashi A., Morita R., Nishizawa S., Tamura Y., Suzuki H., Toyota M., Sato N., Immune response against tumor antigens expressed on human cancer stem-like cells/tumor-initiating cells Immunotherapy 2010 2 2 201 211
122. Engelmann K., Shen H., Finn O. J., MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1 Cancer Research 2008 68 7 2419 2426 (Pubitemid 351521817)
123. Cheever M. A., Allison J. P., Ferris A. S., Finn O. J., Hastings B. M., Hecht T. T., Mellman I., Prindiville S. A., Viner J. L., Weiner L. M., Matrisian L. M., The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research Clinical Cancer Research 2009 15 17 5323 5337
124. Sugiyama H., WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy Japanese Journal of Clinical Oncology 2010 40 5 377 387
125. Correale P., Aquino A., Giuliani A., Pellegrini M., Micheli L., Cusi M. G., Nencini C., Petrioli R., Prete S., De Vecchis L., Turriziani M., Giorgi G., Bonmassar E., Francini G., Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A()02.01 restricted, CEA-peptide-specific Cytotoxic T cells in vitro International Journal of Cancer 2003 104 4 437 445 (Pubitemid 36323913)
126. Correale P., Del Vecchio M. T., La Placa M., Montagnani F., Di Genova G., Savellini G. G., Terrosi C., Mannucci S., Giorgi G., Francini G., Cusiz M. G., Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs Journal of Immunotherapy 2008 31 2 132 147
127. Ramakrishnan R., Gabrilovich D. I., Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer Cancer Immunology, Immunotherapy 2011 60 3 419 423
128. Yanagimoto H., Shiomi H., Satoi S., Mine T., Toyokawa H., Yamamoto T., Tani T., Yamada A., Kwon A. H., Komatsu N., Itoh K., Noguchi M., A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients Oncology Reports 2010 24 3 795 801
129. Hirooka Y., Itoh A., Kawashima H., Hara K., Nonogaki K., Kasugai T., Ohno E., Ishikawa T., Matsubara H., Ishigami M., Katano Y., Ohmiya N., Niwa Y., Yamamoto K., Kaneko T., Nieda M., Yokokawa K., Goto H., A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer Pancreas 2009 38 3 e69 e74
130. Oka Y., Tsuboi A., Taguchi T., Osaki T., Kyo T., Nakajima H., Elisseeva O. A., Oji Y., Kawakami M., Ikegame K., Hosen N., Yoshihira S., Wu F., Fujiki F., Murakami M., Masuda T., Nishida S., Shirakata T., Nakatsuka S. I., Sasaki A., Udaka K., Dohy H., Aozasa K., Noguchi S., Kawase I., Sugiyama H., Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression Proceedings of the National Academy of Sciences of the United States of America 2004 101 38 13885 13890 (Pubitemid 39298502)
131. Takahara A., Koido S., Ito M., Nagasaki E., Sagawa Y., Iwamoto T., Komita H., Ochi T., Fujiwara H., Yasukawa M., Mineno J., Shiku H., Nishida S., Sugiyama H., Tajiri H., Homma S., Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response Cancer Immunology, Immunotherapy 2011 60 9 1289 1297